Introduction
Anthracycline-based chemotherapies can induce immunogenic stress and death in tumor cells, thereby stimulating a protective anticancer immune response (1) . This effect is linked to the capacity of anthracyclines to elicit a series of immunostimulatory stress pathways. Thus, doxorubicin, daunorubicin, epirubicin or mitoxantrone induce autophagic stress (which facilitates the lysosomal secretion of ATP, which then acts on purinergic receptors to attract myeloid cells into the tumor bed) (2), endoplasmic reticulum stress (which stimulates the translocation of the 'eat-me' signal calreticulin to the surface of the plasma membrane, where it facilitates the transfer of tumor antigens to dendritic cells) (3) , the release of HMGB1 from necrotic cells (which stimulates toll-like receptor 4 on dendritic cells, allowing their maturation) (4) , and the stimulation of a type-1 interferon response (which results in the autocrine activation of interferon α/β receptors [IFNAR] for the production of CXCL9 and CXCL10, which in turn stimulates T lymphocyte infiltration into the tumor) (1, 5) . This compendium of signals and pathway explains the unique capacity of anthracyclines to induce anticancer immune responses, both in preclinical models (6, 7) and in breast cancer patients (5, 8) .
The transcription factor STAT3 is considered as a bona fide oncogene because its activation participates in tumorigenesis by virtue of its capacity to inhibit apoptosis and to stimulate unrestrained advancement through the cell cycle, aerobic glycolysis, metastasis (9) (10) (11) . Beyond its capacity to stimulate oncogenesis at the cell-autonomous level, STAT3 has profound effects on the tumor microenvironment by stimulating angiogenesis and inflammation and by mediating immunosuppression (10, 12) . Hence STAT3 activation within tumor cells may contribute to tumor progression. STAT3 activation occurs in multiple immune cell types as well. In TH17 cells, STAT3 activation stimulates the expression of the ectonucleotidases CD39 and CD73, hence augmenting their immunosuppressive actions (13) . In Tregs, STAT3 functionally and physically interacts with FOXP3 (14) , which might explain why STAT3 enhances the function of FOXP3 + Tregs (15) . STAT3 can be activated in distinct myeloid cell types including tumor-associated macrophages and myeloid derived suppress cells, stimulating their immunosuppressive function (16, 17) . In dendritic cells, depletion of STAT3 improves their capacity to present tumor antigens and to stimulate protective anticancer immune responses (18) . As a result, both inhibition of resistance. Forty-eight hours after transfection, G418 (Geneticin® 0.5 mg/ml, Life Technology) was applied for two days to select transfectants. The co-transfection strategy was applied due to the low transfection efficiency of parental cell lines. After a recovery period of 4 days, part of the transfectants was subjected to mismatch-specific nuclease assay with Surveyor mutation detection kit (Transgenomics) to verify the ZFN activity according to the manufacturer's protocol.
STAT3 in cancer cells and in hematopoietic cells (particularly myeloid populations) has been
In brief, genomic DNA was extracted with Kapa DNA extraction kit (Kapa Biosystems).
Genomic region surrounding the Stat3 ZFN target site was amplified with PCR using these primers:
forward Cryostat. Consecutive tissue sections (5 μm) were performed using poly-L-lysine-coated slides.
Immunofluorescence staining were performed as described (30) , with the following antibodies: (Fig. 1A) . This combination effect entirely depended on a T lymphocyte-mediate anticancer immune response, because MCA205 fibrosarcomas implanted in athymic nu/nu mice failed to reduce their growth in response to either DOXO alone or the combination of DOXO plus Stattic (Fig. 1B) .
We used zinc finger nuclease technology to generate several independent clones of MCA205 fibrosarcomas and CT26 colorectal carcinoma cells that lacked Stat3 expression ( Fig. 2A) . Stat3 (Fig. 3B,C) . Similarly, Stat3 -/-MCA205 cells cultured with MTX released normal amounts of HMGB1 (Fig. 3D) . Calreticulin exposure could be induced by MTX in WT and in Stat3 -/-MCA205 cells, although the latter exhibited a reduced calreticulin exposure (Fig. 3E) , correlating with their reduced apoptotic response (Fig. 2B,C; see above) . In sharp contrast, Stat3 -/-MCA205 cells exhibited a marked increase in the expression of genes linked to the type-1 interferon response, as determined by qRT-PCR analyses. This applies to the type-1 interferon gene Ifnb1 itself, the transcription factor Irf7, the antiviral genes Oas2, Mx1, Mx2, the gene coding for the pattern recognition receptor Dhx58, a number of other type-1 interferoninduced genes (such as Ifi205, Ifit2 and Rsad2), as well as to the chemokine-encoding genes Cxcl9 and Cxcl10, which both code for CXCR3 ligands (Fig. 3F) . Interestingly, Stat3 determined by multi-color immunofluorescence, followed by microscopic quantitation (31, 32) ( Fig. 4A) . In spite of the fact that Stat3 -/-MCA205 are less prone to undergo apoptosis in response to anthracyclines in ex-vivo culture (Fig. 2C,D) , the frequency of Casp3a (Fig. 4A,B) .
Similarly, the frequency of CD11c (Fig. 4C,D) . 
STAT3 inhibition and chemotherapy. After anthracycline-based chemotherapy, Stat3
-/-cancers manifested a more dense infiltration by T cells (Fig. 4F) and, more specifically, cytotoxic T lymphocytes (Fig. 4G) reversed the improved chemotherapeutic response to anthracyclines in vivo (Fig. 5) .
Reintroducing WT Stat3 also suppressed the exacerbated type-1 interferon response of Stat3 
Discussion
In this paper, we provide evidence that STAT3 inhibition can synergize with anthracyclines to mediate anticancer effects in preclinical models. Previous studies that were mostly performed in vitro, on cultured human cancer cell lines, suggested that STAT3 activation by anthracyclines may mediate chemoresistance, meaning that inhibition of STAT3 enhances the direct cytotoxic effects of DOXO (34) (35) (36) (37) . Seemingly corroborating this possibility, we found that anthracycline- of type-1 interferon-inducible gene (38) , in line with a model that STAT3 and type I IFN signaling pathway are mutually repressive (39) . In viral infection models, the absence of STAT3 led to hyperactivation of ISGF3 (STAT1:STAT2:IRF9) complex and hence augmented type I IFN response (40, 41) . However, at present it is not known through which detailed molecular mechanisms, STAT3 inhibition amplifies the induction of type-1 interferon-inducible genes by anthracyclines. Hence, this effect of STAT3 inhibition requires further mechanistic exploration.
In line with one previous report (42) , this effect is related to the transcriptional activity of STAT3, because a mutant that lacks transactivation potential was unable to repress the type I IFN response. The amplitude of the stimulatory effect of Stat3 deletion on type-1 interferon-inducible genes is clearly higher when MTX rather than purified IFNα is used as a stimulus. This suggests that the initial events triggered by anthracyclines including the stimulation of pattern recognition receptors (such as TLR3) (5) Tumor growth kinetics was illustrated as means ± SEM. These experiments included at least 5 mice/group and results shown are representative for 2-3 independent experiments. For cell death and tumor growth, the unpaired Student's t-test and the unpaired Mann-Whitney U test, respectively, were applied. *, p<0.05, **, p<0.01, ***, p<0.001, ns, not significant. 
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